Jaehyuk Choi, MD, PhD

Cutaneous T cell lymphoma (CTCL) is an incurable cancer of the immune T cells in the skin. In advanced disease, the cells escape into the blood, the lymph nodes, and at times the visceral organs. Patients with advanced disease eventually succumb to a combination of tumor burden and disease-related immunosuppression. Dr. Choi [Doris Duke-Damon Runyon Clinical Investigator] has recently used next generation sequencing to identify gene mutations that he hypothesizes are important for CTCL pathogenesis.

Sarah (Sadie) M. Wignall, PhD

[Lau/Palihapitiya Innovator]

Cancer cells exhibit uncontrolled growth and proliferation, leading to the formation of malignant tumors. Therefore, many current cancer therapies are aimed at trying to block cell multiplication, with the goal of killing cancerous cells and halting tumor growth. However, many of these treatments also affect the growth and division of non-cancerous cells in the body, leading to severe side effects. 

Oren J. Becher, MD

Diffuse intrinsic pontine glioma, or DIPG, is an incurable brain cancer that mostly strikes young children. The median survival rate is less than one year after diagnosis. To date, there are no chemotherapeutic or targeted agents that have proven to be beneficial for treatment of these cancers. Dr. Becher leads one of very few laboratories around the world that focus exclusively on this type of deadly brain cancer. He has identified EZH2-mediated epigenetic mechanisms that underlie the development of DIPG.